Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Status
- RECRUITING
- Phase
- PHASE3
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
- Status
- RECRUITING
- Phase
- PHASE2
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1/PHASE2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
- Status
- RECRUITING
- Phase
- PHASE2
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Risk Stratification and MRD-driven Maintenance for MM After ASCT
- Status
- RECRUITING
- Phase
- NA